Pfizer Inc. (NYSE:PFE) Shares Sold by Hudock Inc.

Hudock Inc. lowered its position in Pfizer Inc. (NYSE:PFE) by 11.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 42,034 shares of the biopharmaceutical company’s stock after selling 5,215 shares during the quarter. Hudock Inc.’s holdings in Pfizer were worth $1,115,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Retirement Wealth Solutions LLC purchased a new position in Pfizer in the fourth quarter worth approximately $26,000. Gladius Capital Management LP lifted its stake in Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 38,015 shares during the last quarter. Teachers Insurance & Annuity Association of America purchased a new position in Pfizer in the third quarter worth approximately $35,000. Joseph Group Capital Management lifted its stake in Pfizer by 168.3% in the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 771 shares during the last quarter. Finally, Sugar Maple Asset Management LLC purchased a new position in Pfizer in the fourth quarter worth approximately $43,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 0.3 %

PFE stock opened at $25.46 on Thursday. The company has a fifty day moving average price of $26.28 and a 200 day moving average price of $27.65. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a market cap of $144.28 billion, a price-to-earnings ratio of 18.06, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.10 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a $0.43 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a yield of 6.76%. The ex-dividend date is Friday, January 24th. Pfizer’s payout ratio is currently 121.99%.

Analysts Set New Price Targets

A number of brokerages recently issued reports on PFE. Wolfe Research began coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target for the company. Citigroup reduced their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Sanford C. Bernstein initiated coverage on shares of Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective for the company. Guggenheim restated a “buy” rating and set a $33.00 price objective on shares of Pfizer in a research report on Monday. Finally, UBS Group reduced their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.